Abivax S.A.
ABVX
Rang în acțiuni
#2373
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013,... Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Preț acțiune
$93.32
Capitalizare de piață
$8.14B
Schimbare (1 zi)
-1.48%
Schimbare (1 an)
5.60%
Țară
FR
Tranzacționează Abivax S.A. (ABVX)
Categorie
Healthcare
Raport P/B pentru Abivax S.A. (ABVX)
Raport P/B la data de October 2026 TTM: 18.04
Conform celor mai recente rapoarte financiare și prețului acțiunilor Abivax S.A., raportul P/B actual (TTM) este 18.04. La sfârșitul anului 2024, compania avea un P/B de 10.50.
Istoricul raportului P/B pentru Abivax S.A. din 2013 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | 18.04 | -1.91% |
| 2025 | 18.39 | 75.11% |
| 2024 | 10.50 | 386.72% |
| 2023 | 2.16 | -86.85% |
| 2022 | 16.41 | -3.54% |
| 2021 | 17.02 | -38.11% |
| 2020 | 27.50 | 17.92% |
| 2019 | 23.32 | 570.67% |
| 2018 | 3.48 | 96.65% |
| 2017 | 1.77 | 64.90% |
| 2016 | 1.07 | -43.70% |
| 2015 | 1.90 | -55.50% |
| 2014 | 4.28 | -25.24% |
| 2013 | 5.72 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 6.251 | -65.35% |
US
|
|
| 13.2547 | -26.52% |
US
|
|
| 4.4521 | -75.32% |
AU
|
|
| 6.3632 | -64.72% |
NL
|
|
| - | - |
CH
|
